Please wait...
60
62
Offers Claimed: 150
Downloaded Today: 6
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Yes
100% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
$42 – $417
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your myrbetriq prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about mirabegron. Some of the dosage forms listed on this page may not apply to the brand name Myrbetriq.
In SummaryCommon side effects of Myrbetriq include: hypertension. Other side effects include: urinary tract infection. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to mirabegron: oral tablet extended release
Along with its needed effects, mirabegron (the active ingredient contained in Myrbetriq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mirabegron:
More common
Rare
Incidence not known
Some side effects of mirabegron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Rare
For Healthcare Professionals
Applies to mirabegron: oral tablet extended release
GeneralThe more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.
CardiovascularVery common (10% or more): Hypertension (up to 11.3%)
Common (1% to 10%): Tachycardia
Uncommon (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension
In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred. At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.
DermatologicUncommon (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash
Rare (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema
Angioedema of the face, lips, tongue, and/or larynx has been reported. In some case, this occurred after the first dose or after multiple doses.
GastrointestinalCommon (1% to 10%): Nausea, constipation, diarrhea, abdominal pain
Uncommon (0.1% to 1%): Dyspepsia, gastritis, abdominal distension
Rare (less than 0.1%): Lip edema
GenitourinaryCommon (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus
Postmarketing reports: Urinary retention
Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.
MusculoskeletalCommon (1% to 10%): Arthralgia
Uncommon (0.1% to 1%): Joint swelling
Nervous systemCommon (1% to 10%): Headache, fatigue, dizziness
OcularUncommon (0.1% to 1%): Glaucoma, blurred vision, dry eyes
Rare (less than 0.1%): Eyelid edema
OncologicRare (less than 0.1%): Prostate cancer
RespiratoryCommon (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis
HepaticUncommon (0.1% to 1%): Increased ALT, AST, and GGT
PsychiatricThe majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.
Postmarketing reports: Confusion, hallucinations, insomnia, anxiety
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Myrbetriq (www.drugs.com/myrbetriq.html).
August 4, 2022
August 4, 2022
August 4, 2022
July 26, 2022
July 26, 2022
July 22, 2022